The earnings call reflects a positive outlook due to strategic collaborations, promising clinical trial results, and effective cost management, despite the technical difficulties and limited revenue generation. The extension of the cash runway and a new patent for certepetide further bolster confidence in the company's future prospects.

Company Guidance -

Q3 2025

During the Lisata Therapeutics Second Quarter 2025 Financial Results and Business Update Conference Call, the company provided several key metrics and guidance regarding its financial performance and ongoing projects. For the three months ending June 30, 2025, Lisata reported revenue of $70,000 from an upfront license fee with Catalent, Inc., compared to no revenue in the same period in 2024. The company also achieved a decrease in operating expenses, totaling $4.9 million, down from $5.5 million in 2024. Research and development expenses were reduced to $2.3 million, a 13.4% decrease, primarily due to lower patient treatment and clinical research organization costs. General and administrative expenses also decreased by 8.1% to $2.7 million. Overall, Lisata's net loss for the quarter was $4.7 million, compared to $5 million in the prior year. The company reported cash, cash equivalents, and marketable securities of approximately $22 million as of June 30, 2025, and believes these funds will support operations into the fourth quarter of 2026. The call also highlighted encouraging preliminary results from the ASCEND and iLSTA trials, as well as strategic collaborations and regulatory progress, setting the stage for a data-rich upcoming year with several anticipated milestones.

Strategic Collaborations and Alliances

Lisata signed a research agreement with Catalent and formed a strategic alliance with GATC Health, exploring synergies and employing AI for new drug development candidates.

Encouraging Clinical Trial Results

Preliminary results from the ASCEND and iLSTA trials were encouraging, validating certepetide's promise with positive signals in survival and objective response rates.

Reduced Operating Expenses

Operating expenses decreased by 10.6% from $5.5 million in Q2 2024 to $4.9 million in Q2 2025, driven by reductions in R&D and general administrative costs.

Extended Cash Runway

Cash and equivalents of approximately $22 million are expected to support operations into Q4 2026, extending the previous runway estimate.

New Patent for Certepetide

A new composition of matter patent for certepetide was granted, extending protection until March 2040, securing exclusive rights.

Lisata Therapeutics (LSTA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LSTA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.59 / -	-0.59	―	―	―
Aug 07, 2025	2025 (Q2)	-0.65 / -0.54	-0.61	11.48% (+0.07)	―
May 08, 2025	2025 (Q1)	-0.53 / -0.55	-0.65	15.38% (+0.10)
Feb 27, 2025	2024 (Q4)	-0.76 / -0.55	-0.66	16.67% (+0.11)
Nov 12, 2024	2024 (Q3)	-0.75 / -0.59	-0.65	9.23% (+0.06)
Aug 12, 2024	2024 (Q2)	-0.75 / -0.61	-0.5	-22.00% (-0.11)
May 09, 2024	2024 (Q1)	-0.72 / -0.65	-0.77	15.58% (+0.12)
Feb 29, 2024	2023 (Q4)	-0.85 / -0.66	-0.76	13.16% (+0.10)
Nov 02, 2023	2023 (Q3)	-0.93 / -0.65	-7.88	91.75% (+7.23)
Aug 14, 2023	2023 (Q2)	-0.70 / -0.50	-1.65	69.70% (+1.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LSTA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$2.80	$2.60	-7.14%
May 08, 2025	$2.37	$2.10	-11.39%
Feb 27, 2025	$2.40	$2.38	-0.83%
Nov 12, 2024	$2.91	$2.79	-4.12%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lisata Therapeutics (LSTA) report earnings?

Lisata Therapeutics (LSTA) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Lisata Therapeutics (LSTA) earnings time?

Lisata Therapeutics (LSTA) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LSTA EPS forecast?

LSTA EPS forecast for the fiscal quarter 2025 (Q3) is -0.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing